Among these, NKG2A could be a relevant candidate target due to its overexpression in about 15% of CD8+ TILs in CRC (often associated with HLA-E) and its strong impact on inhibiting anti-tumor T responses [21,23]. Here, CD8A is linked to neoplasm.